Skip to content
UplinkBets UK

Individuals Discontinuing Anti-Obesity Medications Put On Weight at a Quadrupled Rate Than People Using Diet and Exercise

Image of pharmaceutical injection and weighing machine
Obesity treatment involves long-term strategies.

Fresh analysis reveals that people who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who stop traditional diet and exercise programs.

Published data in a major medical journal demonstrates that while overweight people frequently drop a large proportion of their total mass while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month after stopping.

"Users buying these drugs must be informed of the potential of quick rebound weight gain when the therapy is stopped," stated researcher Dr. Susan Jebb.

This pace of regain suggests a return to original mass within about one and a half years.

Weighing Approaches

The analysis, which examined dozens of trials involving thousands of participants, compared the effects of GLP-1 agonists with conventional dieting.

The team note that people who lose weight through lifestyle changes alone generally experience a slower weight regain—approximately 100 grams monthly—after stopping.

Explaining the Fast Regain

Experts suggest the mechanism of the drugs explains the accelerated rebound.

GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate appetite.

"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this medication results in hunger is no longer kept in check, making excessive eating far more likely."

A Lifelong Issue?

Health authorities recommend the injections for people with weight-linked medical conditions, alongside prescribed lifestyle changes.

A number of clinicians contend that, due to the high risk of relapse, the therapy is often ongoing.

This opinion is supported by drug manufacturers, who say that the results "highlight the chronic character of obesity," akin to managing conditions like high blood pressure.

Patient Accounts

Individuals who have discontinued the jabs describe a sudden resurgence of hunger.

"It was like something activating and you're instantly starving," recalled one woman.

This difficulty is exacerbated if individuals have not developed lasting lifestyle or habit modifications during treatment.

Widespread Adoption

Recent estimates indicate that millions of people in the UK have used these injections in the past year, with desire being substantial.

  • Adoption is greater among women compared to males.
  • The 40s and 50s demographic shows the highest level of interest.
  • Many access the medications through private prescriptions rather than public health services.

Finally, researchers caution that while GLP-1 drugs are effective tools for weight loss, they are not a magic fix and lasting health benefits hinges on ongoing behavioural support.

TH
By

Theresa Harvey

A seasoned sports analyst with over a decade of experience in betting markets, specializing in football and horse racing strategies.

UplinkBets UK

Type to search articles.